Spyre Therapeutics
United States
About Spyre Therapeutics
131 articles about Spyre Therapeutics
-
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
1/6/2020
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, announced it will present at the 38th Annual J.P. Morgan Healthcare Conference to be held January 13-16 in San Francisco, CA.
-
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
11/6/2019
Today reported financial results for the third quarter ended September 30, 2019 and corporate highlights.
-
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
11/4/2019
The Company welcomes Dr. Ravi M. Rao as chief medical officer and Michael C. Hanley as chief commercial officer.
-
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
-
Gemini Therapeutics Strengthens Senior Leadership Team with Key Appointments and Promotion
5/30/2018
Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.
-
Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.
-
Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase I/II Trial with Pegzilarginase (AEB1102)
11/29/2017
Clinical agreement reached with FDA to enable pediatric dosing.
-
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
11/8/2017
On September 30, 2017, Aeglea had available cash, cash equivalents and marketable securities of $55.7 million.
-
Aeglea BioTherapeutics Inks Clinical Collaboration with Merck
10/16/2017
Aeglea and Merck will evaluate the combination of Aeglea's AEB1102 with Merck’s anti-PD-1 therapy, KEYTRUDA for the treatment of patients with small cell lung cancer.
-
Aeglea Doses Two Patients In Repeat Dose Part Of Phase I/II Clinical Trial For The Treatment Of Arginase 1 Deficiency
9/6/2017
-
Aeglea Appoints James Wooldridge, M.D. As Chief Medical Officer
7/11/2017
-
Aeglea Prices Public Offering Of Common Stock
6/6/2017
-
Aeglea Announces Proposed Public Offering Of Common Stock
6/6/2017
-
Aeglea Provides AEB1102 Program And Corporate Update
5/23/2017
-
Aeglea Provides Corporate Update And Reports First Quarter 2017 Financial Results
5/9/2017
-
Everything's Bigger in Texas: Aeglea Quickly Growing into Leading Austin Biotech
9/14/2016
-
Aeglea Announces Closing Of Initial Public Offering And Partial Exercise Of The Underwriters’ Option
4/13/2016
-
Aeglea Appoints Dr. Anthony Quinn To Board Of Directors
3/15/2016
-
Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Hematological Malignancies
3/15/2016
-
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.